Management of cytomegalovirus infection and disease in liver transplant recipients
Open Access
- 1 January 2014
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 6 (6), 370-83
- https://doi.org/10.4254/wjh.v6.i6.370
Abstract
Cytomegalovirus (CMV) is one of the most common viral pathogens causing clinical disease in liver transplant recipients, and contributing to substantial morbidity and occasional mortality. CMV causes febrile illness often accompanied by bone marrow suppression, and in some cases, invades tissues including the transplanted liver allograft. In addition, CMV has been significantly associated with an increased predisposition to acute and chronic allograft rejection, accelerated hepatitis C recurrence, and other opportunistic infections, as well as reduced overall patient and allograft survival. To negate the adverse effects of CMV infection on transplant outcome, its prevention, whether through antiviral prophylaxis or preemptive therapy, is an essential component to the management of liver transplant recipients. Two recently updated guidelines have suggested that antiviral prophylaxis or preemptive therapy are similarly effective in preventing CMV disease in modest-risk CMV-seropositive liver transplant recipients, while antiviral prophylaxis is the preferred strategy over preemptive therapy for the prevention of CMV disease in high-risk recipients [CMV-seronegative recipients of liver allografts from CMV-seropositive donors (D+/R-)]. However, antiviral prophylaxis has only delayed the onset of CMV disease in many CMV D+/R- liver transplant recipients, and such occurrence of late-onset CMV disease was significantly associated with increased all-cause and infection-related mortality after liver transplantation. Therefore, a search for better strategies for prevention, such as prolonged duration of antiviral prophylaxis, a hybrid approach (antiviral prophylaxis followed by preemptive therapy), or the use of immunologic measures to guide antiviral prophylaxis has been suggested to prevent late-onset CMV disease. The standard treatment of CMV disease consists of intravenous ganciclovir or oral valganciclovir, and if feasible, reduction in pharmacologic immunosuppression. In one clinical trial, oral valganciclovir was as effective as intravenous ganciclovir for the treatment of mild to moderate CMV disease in solid organ (including liver) transplant recipients. The aim of this article is to provide a state-of-the art review of the epidemiology, diagnosis, prevention, and treatment of CMV infection and disease after liver transplantation.Keywords
This publication has 104 references indexed in Scilit:
- Updated International Consensus Guidelines on the Management of Cytomegalovirus in Solid-Organ TransplantationTransplantation, 2013
- Cytomegalovirus in Solid Organ TransplantationAmerican Journal of Transplantation, 2013
- First Pharmacokinetic and Safety Study in Humans of the Novel Lipid Antiviral Conjugate CMX001, a Broad-Spectrum Oral Drug Active against Double-Stranded DNA VirusesAntimicrobial Agents and Chemotherapy, 2012
- Homozygosity for the Toll-Like Receptor 2 R753Q Single-Nucleotide Polymorphism Is a Risk Factor for Cytomegalovirus Disease After Liver TransplantationThe Journal of Infectious Diseases, 2012
- Delayed-Onset Primary Cytomegalovirus Disease and the Risk of Allograft Failure and Mortality after Kidney TransplantationClinical Infectious Diseases, 2008
- Lipopolysaccharide, Tumor Necrosis Factor Alpha, or Interleukin-1β Triggers Reactivation of Latent Cytomegalovirus in Immunocompetent MiceJournal of Virology, 2006
- Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection?Liver Transplantation, 2005
- In vitro cytokine production of TNFα and IL-13 correlates with Acute liver transplant rejectionHuman Immunology, 2001
- CYTOMEGALOVIRUS ANTIGENEMIA DIRECTED PRE-EMPTIVE PROPHYLAXIS WITH ORAL VERSUS I.V. GANCICLOVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN LIVER TRANSPLANT RECIPIENTS1Transplantation, 2000
- OKT3 Treatment for Allograft Rejection Is a Risk Factor for Cytomegalovirus Disease in Liver TransplantationThe Journal of Infectious Diseases, 1995